Elicera Therapeutics AB (ELIC) — Cash Flow-to-Debt Ratio
Elicera Therapeutics AB (ELIC) has a Cash Flow-to-Debt Ratio of -0.68x as of September 2025, meaning its operating cash flow of Skr-4.74 Million could theoretically repay -1% of its total liabilities (Skr6.97 Million) in one year. See ELIC cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Elicera Therapeutics AB Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Elicera Therapeutics AB across 8 annual periods. Also explore Elicera Therapeutics AB annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Elicera Therapeutics AB (2017–2024)
Year-by-year debt coverage analysis for Elicera Therapeutics AB. For market capitalisation and broader financial context, see ELIC market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.45x | Skr-23.46 Million | Skr6.79 Million | ▼ -219.0% |
| 2023 | -1.08x | Skr-14.92 Million | Skr13.78 Million | ▼ -70.7% |
| 2022 | -0.63x | Skr-8.57 Million | Skr13.51 Million | ▲ +88.9% |
| 2021 | -5.72x | Skr-14.29 Million | Skr2.50 Million | ▼ -1386.4% |
| 2020 | -0.38x | Skr-905.25K | Skr2.35 Million | ▲ +99.4% |
| 2019 | -59.79x | Skr-239.16K | Skr4.00K | ▲ +0.0% |
| 2018 | -59.79x | Skr-239.16K | Skr4.00K | ▲ +0.0% |
| 2017 | -59.79x | Skr-239.16K | Skr4.00K | — |